No profile data available.
Vaxart, Inc. (VXRT) is a healthcare company in the antiviral pharmaceuticals industry, based in South San Francisco, United States, with about 65 full-time employees.
It reported revenue of $237.26 million for fiscal year 2025, up 726.7% from fiscal year 2024, and net income of $16.33 million. Its market capitalization was $104.79 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform.
Vaxart reported $237.26 million in revenue for fiscal year 2025, up 726.7% from $28.70 million in fiscal year 2024.
$104.79 million as of October 9, 2026.
Listed companies of a similar size in the same industry (antiviral pharmaceuticals) include InflaRx N.v. (IFRX), Siga Technologies, Inc. (SIGA), Invivyd, Inc. (IVVD), Verrica Pharmaceuticals Inc. (VRCA).